3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
3
Unknown
1
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
50
Pancreatic Neoplasms
14
Neoplasms
11
Lung Neoplasms
11
Neoplasm Metastasis
7
Breast Neoplasms
6
Brain Neoplasms
6
Head and Neck Neoplasms
4
Gliosarcoma
4
Glioblastoma
4
Carcinoma, Hepatocellular
4
Squamous Cell Carcinoma of Head and Neck
3
Recurrence
3
Neuroendocrine Tumors
3
Colorectal Neoplasms
3
Carcinoma, Squamous Cell
3
Prostatic Neoplasms
2
Oligodendroglioma
2
Non-Squamous Non-Small Cell Lung Cancer
2
Glioma
2
Familial ependymoma
2
Esophageal Neoplasms
2
Ependymoma
2
Carcinoma, Renal Cell
2
Carcinoma
2
Carcinoid Tumor
2
Astrocytoma
2
Urinary Bladder Neoplasms
1
Thrombocytosis
1
Thoracic Neoplasms
1
Interventions
Pemetrexed
3
Carboplatin
3
osimertinib
2
pralsetinib
1
pembrolizumab
1
patritumab
1
alectinib
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Gemcitabine
1
Erlotinib Hydrochloride
1
Cisplatin
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Respiratory Tract Diseases
×
Erlotinib Hydrochloride
×
Clear all
NCT02134015
2018-01-23
HER3-Lung
Daiichi Sankyo
Phase 3
Terminated
145 enrolled
20 charts